Previous 10 | Next 10 |
Pulse Biosciences (NASDAQ: PLSE ): Q3 Non-GAAP EPS of -$0.57 beats by $0.04 . Cash and cash equivalents of $9.57M. Shares -2.5% Press Release More news on: Pulse Biosciences, Inc., Earnings news and commentary, Healthcare stocks news,
Company announces the appointment of Sandra Gardiner as Chief Financial Officer Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System, announced today that Sandra (“Sandy”...
Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System, announced today that the Company will report third quarter 2019 operational updates and hig...
-- Nano-Pulse Stimulation Technology Highlights Plenary Talk on “Emerging Therapies in Dermatologic Surgery” Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System harnessing Nano-Pulse Stimulati...
-- Histological Effects of NPS-Treated Dermal Skin on Sebaceous Glands and Sebaceous Hyperplasia Lesions Spotlights “Facial Rejuvenation” Session at the American Academy of Facial Plastic and Reconstructive Surgery Annual Meeting -- NPS Technology Headlines “New and...
With one product candidate at Phase 3 of development and expecting completion in early 2020, Aclaris Therapeutics ( ACRS ) is a name to be followed carefully. The Phase 3 trial is estimated to be completed on January 15, 2020. With that said, the company’s cash burn rate is very signifi...
Pulse Biosciences, Inc(PLSE) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Brian Dow – Senior Vice President and Chief Financial Officer Darrin Uecker – President and Chief Executive Officer Ed Ebbers – Executive Vice Preside...
Pulse Biosciences (NASDAQ: PLSE ): Q2 GAAP EPS of -$0.55 misses by $1.06 . More news on: Pulse Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company”), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System, today reported recent corporate developments and financial resul...
Pulse Biosciences, Inc . (NASDAQ:PLSE), a bioelectric medicine technology company bringing to market its proprietary CellFX™ System, today announced its patented Nano-Pulse Stimulation™ (NPS™) technology will be featured in a series of podium presentations in the “...
News, Short Squeeze, Breakout and More Instantly...
Pulse Biosciences Inc Company Name:
PLSE Stock Symbol:
NASDAQ Market:
Pulse Biosciences Inc Website:
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the second quarter 2024 after market close on Monday, August 12, 2024. Company managemen...
2024-07-15 17:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...